Measuring how proteins are replaced in healthy adults over time
Official title: Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide
Run by National Institutes of Health Clinical Center (CC) · NCT06269653 · Data updated 2026-11-12
This study is testing how quickly proteins are replaced in healthy adults of different ages to see how aging affects this process.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years to 120 Years |
| Sex | All |
| Enrollment | 75 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Baltimore, Maryland) |
| Status | Recruiting |
| Started | June 26, 2024 |
| Main results expected | March 1, 2027 |
| Study ends | March 1, 2027 |
| Registry record updated | March 20, 2026 |
| Trial ID | NCT06269653 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy adults aged 20 years and older with a BMI between 20 and 30.
✕Probably not a fit
Patients with a history of increased bleeding, those taking NSAIDs regularly, or individuals with certain health conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to measure protein turnover rates in healthy adults aged 20 and older. Participants will undergo a series of assessments, including physical exams and blood tests, over 4 to 6 weeks, during which they will consume heavy water to track protein turnover. The study will evaluate how aging affects the half-life of proteins in various tissues, including muscle and skin, and will explore differences in protein turnover between younger and older individuals.
Why it matters
Potential benefit: If successful, this study could provide insights into how aging impacts protein turnover, potentially leading to better understanding of age-related health issues.
How similar studies have gone: While studies on protein turnover exist, this specific approach of measuring turnover across different tissues and ages is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: To be eligible to participate in this study, an individual must meet all the following criteria: * Stated willingness to comply with all study procedures and availability for the duration of the study. * Male or female, age \>= 20years. * BMI \>20 and \<30. * In good general health as evidenced by medical history/exam/laboratory. * IL6\< 3.5 pg/mL. * Ankle Brachial Index (ABI) \> 0.9. * No history of increased bleeding due to either a known medical condition or an undiagnosed cause. * Does not currently smoke/tobacco use. * Eligible for muscle biopsy procedures. * Is not allergic to lidocaine or other local anesthetics. * Able to speak and read English. * Ability of subject to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * Routinely taking (more than 2x/week) non-steroidal anti-inflammatory agents (NSAIDs) and unwilling to stop taking them for the duration of the study. * Taking medications that could increase the chance of bleeding such as anticoagulants/antiplatelet such as Coumadin, Plavix, and Heparin. Low dose (81mg) aspirin use is okay. * Is unable to reach down to perform wound care of the lower legs. * Has laboratory evidence of diabetes at screening (fasting glucose \>= 126) and/or diabetes requiring treatment, or treatment with any glucose lowering drug(s). * Has current or history of inflammatory and/or autoimmune diseases. * History of keloid formation. * Researchers are unable to access biopsy sites due to conditions such as wounds, rashes, or large deposits of adipose tissue. * Is on treatment with an investigational drug or other intervention within 8 weeks of enrollment. * Has any chronic disease that the study PI considers as a significant comorbidity that affects health and life expectancy. * Has established genetic diseases such as sickle cell, hemochromatosis (iron overload), cystic fibrosis or Ehlers-Danlos syndrome (connective tissue disorder). * Has autoimmune diseases such as Hashimoto s thyroiditis, Myasthenia Gravis, or Rheumatoid arthritis. * Has severe mobility disability as evidenced by inability to walk without aids, perform activities of daily living and to reach down to lower legs to perform wound care. * Has had active cancer on treatment in the last 10 years. * Has muscle-skeletal conditions due to diseases or traumas (that cause pathological weakness and/or chronic pain). * Has any medical condition that requires absolute and continuous need for long term treatment with antibiotics, corticosteroids, immunosuppressors, or pain medications. * Has important sensory deficits such as legally blind. * Is currently pregnant or a nursing mother. * Has history of, or laboratory evidence of HIV, Hepatitis B or C at Screening. * Has laboratory evidence of Platelets \< 100,000 or \>600,000 k/microliter. * Has a positive urine drug screen unless taking prescribed medication and at the discretion of the PI. * Has a current illness that as judged by the study physician substantially increases the risks associated with performing a biopsy procedure. * Has a history of an active bleeding disorder such as haemophilia or Von Willebrand disease. * Is claustrophobic and/or is not eligible to perform MRI as per the MRI eligibility form. * Has a hip or knee replacement or other medical conditions that prevents MRI research scans from being performed. * Has a diagnosis of cognitive impairment that clearly prevents the participant from providing informed consent. * Has a history of, or evidence of heart disease including unstable angina, myocardial infarction, congestive heart failure, cerebrovascular diseases, uncontrolled hypertension, uncontrolled cardiac arrythmias, moderate to severe valvular disease. * Has a history or has chronic liver disease as evidenced by medical history or ALT, AST, or alkaline phosphatase twice the normal serum concentration. * Drinks more than three drinks of alcohol per day on average. * Has a history of, or evidence of chronic kidney disease or serum creatinine \>1.1 mg/dL. Participants must be able to speak and read English. The reason for this is for safety reasons especially as it relates to the muscle biopsy procedures. Participants will be required to provide medication history and to understand and report any problems post muscle biopsy to the research medical staff. In addition, the medical staff will be contacting the participant after the biopsies to ensure that they are recovering and do not have significant side effects for which the participant must be able to clearly verbalize for the medical staff to determine if additional observation or treatment is indicated.
Where it's running
-
National Institute of Aging, Clinical Research Unit
Baltimore, Maryland, United States Recruiting
Study contacts
- Principal investigator: Luigi Ferrucci, M.D. — National Institute on Aging (NIA)
- Study coordinator: Linda M Zukley, Ph.D.
- Email: zukleylm@mail.nih.gov
- Phone: (410) 350-3983
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of Exercise Snacks on Muscle Size and Strength in Healthy Young Adults
This study tests whether many small workouts throughout the week can build muscle size and improve strength in healthy, untrained young adults compared with the usual twice-weekly workouts.
-
ORX489 safety and dosing in healthy adults ages 18 to 60
This will test whether ORX489 tablets are safe, well tolerated, and how they are processed in the body in healthy men and women aged 18 to 60.
-
ReHIIT Prehabilitation in Healthy Adults
This pilot tests a combined resistance and high‑intensity interval training program to establish baseline physiology in healthy adults before applying findings to cancer patients.
-
Safety and drug levels of a 3‑month naltrexone implant (BICX104) with or without bupropion versus monthly Vivitrol injections
This will test whether a three‑month naltrexone implant (BICX104), given alone or with extended‑release bupropion, is safe and keeps steady drug levels compared with monthly Vivitrol injections in healthy adults.
-
Compare two forms and doses of vonafexor and see if the high dose interacts with other drugs
This test looks at how two doses and two formulations of vonafexor (EYP651 and vonafexor acid) are absorbed and processed in healthy adults and whether the high dose interacts with common medicines.
-
Low-frequency vibrating mat for sleep and daily stress recovery
This test will see if using a low-frequency vibrating mat at home for three weeks improves stress recovery, sleep quality, mood, and attention in healthy adults aged 18-45.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.